Page 85 - 2019_12-Haematologica-web

Hydroxyurea in polycythemia vera
januskinase-2 or calreticulin gene at the uni- versity hospital Krems from 2008 to 2015. Oncotarget. 2018;9(9):8450-8462.
30. Linardi CCG, Pracchia LF, Buccheri V. Diagnosis and treatment of polycythemia vera: Brazilian experience from a single insti- tution. Sao Paulo Med J. 2008;126(1):52-57.
31. Lussana F, Carobbio A, Randi ML, et al. A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera. Br J Haematol. 2014;167(4):541-546.
32. Podoltsev NA, Zhu M, Zeidan AM, et al. The impact of phlebotomy and hydrox- yurea on survival and risk of thrombosis among older patients with polycythemia
vera. Blood Adv. 2018;2(20):2681-2690.
33. Tefferi A, Rumi E, Finazzi G, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an inter- national study. Leukemia. 2013;27(9):1874-
1881.
34. Marchioli R, Finazzi G, Landolfi R, et al.
Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23(10):2224-2232.
35. Barbui T, Vannucchi AM, Carobbio A, et al. Patterns of presentation and thrombosis out- come in patients with polycythemia vera strictly defined by WHO-criteria and strati- fied by calendar period of diagnosis. Am J Hematol. 2015;90(5):434-437.
36. Lambert PC, Sutton AJ, Abrams KR, Jones DR. A comparison of summary patient-level covariates in meta-regression with individ- ual patient data meta-analysis. J Clin Epidemiol. 2002;55(1):86-94.
37. Raskob GE, Angchaisuksiri P, Blanco AN. Thrombosis: a major contributor to the global disease burden. Arter Thromb Vasc Biol. 2014;34(11):2363-2371.
38. Wendelboe AM, Raskob GE. Global burden of thrombosis: epidemiologic aspects. Circ Res. 2016;118(9):1340-1347.
39. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median , range , and the size of a sample. BMC Med Res Methodol. 2005,5:13.
haematologica | 2019; 104(12)
2399